Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment, and you are unlikely to be protected if something goes wrong.

Take two mins to learn more

Investment Track Record

Investment Track Record

Investment Track Record

We back founders in:

We back founders in:

We back founders in:

Life Science

Life Science

Food & Agriculture

Food & Agriculture

Sustainable Materials

Sustainable Materials

Hardware & Software

Hardware & Software

Advanced Manufacturing

Advanced Manufacturing

Descycle
Descycle
Descycle
MarraBio
MarraBio
MarraBio
Evoralis
Evoralis
Evoralis
BiologIC
BiologIC
BiologIC
Qkine
Qkine
Qkine
Q5D
Q5D
Q5D
Floreon
Floreon
Floreon

Descycle

Revolutionising electronic waste recycling, Descycle employs Deep Eutectic Solvents for an eco-friendly, swift, and capital-efficient process. With disruptive environmental and economic advantages, Descycle leads the way in sustainable solutions for the electronic waste market.

Why did we invest in Descycle?

Experienced and well-balanced management team.

Strategic alignment and value-add through scale up support from CPI.

Targeting a well-defined and clear need for innovation in a growing market area.

Joint Venture Agreement in place with a UK e-waste processing facility.

High impact potential with sustainability at the core of business activities.

Acquisitive market with trade acquirers paying premium prices for strategic assets.

A black and white photo of two men in lab coats inspecting a bio-reactor
A close up photo of a circuit board that can be recycled using Deep Eutectic Solvents
Photo showing the Deep Eutectic Solvents proccess

Descycle

Revolutionising electronic waste recycling, Descycle employs Deep Eutectic Solvents for an eco-friendly, swift, and capital-efficient process. With disruptive environmental and economic advantages, Descycle leads the way in sustainable solutions for the electronic waste market.

Why did we invest in Descycle?

Experienced and well-balanced management team.

Strategic alignment and value-add through scale up support from CPI.

Targeting a well-defined and clear need for innovation in a growing market area.

Joint Venture Agreement in place with a UK e-waste processing facility.

High impact potential with sustainability at the core of business activities.

Acquisitive market with trade acquirers paying premium prices for strategic assets.

A black and white photo of two men in lab coats inspecting a bio-reactor
A close up photo of a circuit board that can be recycled using Deep Eutectic Solvents
Photo showing the Deep Eutectic Solvents proccess

Descycle

Revolutionising electronic waste recycling, Descycle employs Deep Eutectic Solvents for an eco-friendly, swift, and capital-efficient process. With disruptive environmental and economic advantages, Descycle leads the way in sustainable solutions for the electronic waste market.

Why did we invest in Descycle?

Experienced and well-balanced management team.

Strategic alignment and value-add through scale up support from CPI.

Targeting a well-defined and clear need for innovation in a growing market area.

Joint Venture Agreement in place with a UK e-waste processing facility.

High impact potential with sustainability at the core of business activities.

Acquisitive market with trade acquirers paying premium prices for strategic assets.

A black and white photo of two men in lab coats inspecting a bio-reactor
A close up photo of a circuit board that can be recycled using Deep Eutectic Solvents
Photo showing the Deep Eutectic Solvents proccess
A greyscale team photo of the Qkine team

Qkine

At the forefront of stem cell therapy and regenerative medicine, Qkine manufactures high-purity, animal-free growth factors. Their expertise in protein purification and structural biology has confirmed their status as a key player in the growth factor market, with over 40 products on the market.

Why did we invest in Qkine?

Experienced female CEO with a proven track record of laboratory and manufacturing growth.

Growing and multi-faceted markets with multiple areas of expansion.

Over 40 products on the market supported by a strong R&D pipeline.

Credible investor base.

Alignment with CPI’s technical capabilities and areas of strategic focus.

A greyscale team photo of the Qkine team

Qkine

At the forefront of stem cell therapy and regenerative medicine, Qkine manufactures high-purity, animal-free growth factors. Their expertise in protein purification and structural biology has confirmed their status as a key player in the growth factor market, with over 40 products on the market.

Why did we invest in Qkine?

Experienced female CEO with a proven track record of laboratory and manufacturing growth.

Growing and multi-faceted markets with multiple areas of expansion.

Over 40 products on the market supported by a strong R&D pipeline.

Credible investor base.

Alignment with CPI’s technical capabilities and areas of strategic focus.

Qkine

Qkine

At the forefront of stem cell therapy and regenerative medicine, Qkine manufactures high-purity, animal-free growth factors. Their expertise in protein purification and structural biology has confirmed their status as a key player in the growth factor market, with over 40 products on the market.

At the forefront of stem cell therapy and regenerative medicine, Qkine manufactures high-purity, animal-free growth factors. Their expertise in protein purification and structural biology has confirmed their status as a key player in the growth factor market, with over 40 products on the market.

Why did we invest in Qkine?

Experienced female CEO with a proven track record of laboratory and manufacturing growth.

Experienced female CEO with a proven track record of laboratory and manufacturing growth.

Growing and multi-faceted markets with multiple areas of expansion.

Growing and multi-faceted markets with multiple areas of expansion.

Over 40 products on the market supported by a strong R&D pipeline.

Over 40 products on the market supported by a strong R&D pipeline.

Credible investor base.

Credible investor base.

Alignment with CPI’s technical capabilities and areas of strategic focus.

Alignment with CPI’s technical capabilities and areas of strategic focus.

Q5D

Redefining additive manufacturing, Q5D's 5-axis robotic platform automates wiring and printed electronics, significantly reducing costs and reliance on manual labour. Their technology is pivotal in meeting the increasing demand for electrical connections in the automotive industry.

Why did we invest in Q5D?

Innovative and novel technology developed from commercial insights.

Clear market needs with a proven application of technology.

Commercial traction through projects with corporates across various sectors.

Alignment with CPI’s Formulation capabilities.

Credible investor base.

A team photo of the Q5D team
A close up photo of a printed electronics circuit board
A photo of the inside of an aircraft cabin

Q5D

Redefining additive manufacturing, Q5D's 5-axis robotic platform automates wiring and printed electronics, significantly reducing costs and reliance on manual labour. Their technology is pivotal in meeting the increasing demand for electrical connections in the automotive industry.

Why did we invest in Q5D?

Innovative and novel technology developed from commercial insights.

Clear market needs with a proven application of technology.

Commercial traction through projects with corporates across various sectors.

Alignment with CPI’s Formulation capabilities.

Credible investor base.

A team photo of the Q5D team
A close up photo of a printed electronics circuit board
A photo of the inside of an aircraft cabin

Q5D

Redefining additive manufacturing, Q5D's 5-axis robotic platform automates wiring and printed electronics, significantly reducing costs and reliance on manual labour. Their technology is pivotal in meeting the increasing demand for electrical connections in the automotive industry.

Why did we invest in Q5D?

Innovative and novel technology developed from commercial insights.

Clear market needs with a proven application of technology.

Commercial traction through projects with corporates across various sectors.

Alignment with CPI’s Formulation capabilities.

Credible investor base.

A team photo of the Q5D team
A close up photo of a printed electronics circuit board
A photo of the inside of an aircraft cabin
A photo of an experiment involving alternative proteins

MarraBio

A pioneer in engineering multimeric proteins, MarraBio utilises a proprietary E. coli-based technology for a diverse number of applications. From cell culture reagents to low-cost growth factors for cultivated meat production, the company is poised to make a profound impact in the biotechnology arena.

Why did we invest in MarraBio?

Innovative and novel technology developed from university research.

Strategic alignment with CPI.

Strong management team, integral to the technical development.

Expansive market with early market interest.

A photo of an experiment involving alternative proteins

MarraBio

A pioneer in engineering multimeric proteins, MarraBio utilises a proprietary E. coli-based technology for a diverse number of applications. From cell culture reagents to low-cost growth factors for cultivated meat production, the company is poised to make a profound impact in the biotechnology arena.

Why did we invest in MarraBio?

Innovative and novel technology developed from university research.

Strategic alignment with CPI.

Strong management team, integral to the technical development.

Expansive market with early market interest.

MarraBio

MarraBio

A pioneer in engineering multimeric proteins, MarraBio utilises a proprietary E. coli-based technology for a diverse number of applications. From cell culture reagents to low-cost growth factors for cultivated meat production, the company is poised to make a profound impact in the biotechnology arena.

A pioneer in engineering multimeric proteins, MarraBio utilises a proprietary E. coli-based technology for a diverse number of applications. From cell culture reagents to low-cost growth factors for cultivated meat production, the company is poised to make a profound impact in the biotechnology arena.

Why did we invest in MarraBio?

Innovative and novel technology developed from university research.

Innovative and novel technology developed from university research.

Strategic alignment with CPI.

Strategic alignment with CPI.

Strong management team, integral to the technical development.

Strong management team, integral to the technical development.

Expansive market with early market interest.

Expansive market with early market interest.

INFORMATION MEMORANDUM

Download Investment Brochure

We are delighted to share the latest edition of the EverQuest EIS Fund Information Memorandum.

By choosing EverQuest as your investment partner, you become integral to our aim to have a real contribution to our world.

By submitting you agree that the email provided is subject to our Privacy Policy.

Download Investment Brochure

We are delighted to share the latest edition of the EverQuest EIS Fund Information Memorandum.

By choosing EverQuest as your investment partner, you become integral to our aim to have a real contribution to our world.

By submitting you agree that the email provided is subject to our Privacy Policy.

Download Investment Brochure

We are delighted to share the latest edition of the EverQuest EIS Fund Information Memorandum.

By choosing EverQuest as your investment partner, you become integral to our aim to have a real contribution to our world.

By submitting you agree that the email provided is subject to our Privacy Policy.

Get in Touch with Our Team.

Get in Touch with Our Team.

Get in Touch with Our Team.

EverQuest Capital Partners Logo

Transforming

industry.

Creating

legacy.

Subscribe to Newsletter

By subscribing you agree that the email provided is subject to our Privacy Policy.

Copyright ©2026. EverQuest Capital Partners

EverQuest Capital Partners LLP ("we", "us", "our") is an appointed representative of Enterprise Investment Partners LLP which is authorised and regulated by the Financial Conduct Authority ("FCA") under firm reference number FRN:604439 Our firm reference number is FRN: 1018153.

This website contains financial promotions that have been approved by Enterprise Investment Partners LLP for the purposes of section 21 of the Financial Services and Markets Act 2000. The information on this website is directed only at persons in the United Kingdom who are:

- Professional clients or eligible counterparties as defined by the FCA; or

- Certified high net worth individuals, self-certified sophisticated investors, or other persons to whom financial promotions may lawfully be made under the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005.


This website and any materials or information contained herein do not constitute an offer to the public or a financial promotion to retail clients unless they meet the criteria above, nor does it constitute a Direct Offer Financial Promotion. Applications for investment may only be made on the basis of the relevant documentation, copies of which are available on request. No reliance is to be placed on the information contained in this website in making such an application.

Investments of the kind referred to in this website are high-risk and are not suitable for all investors. Such investments may be illiquid, volatile, and carry a risk of total loss of capital. Past performance is not a reliable indicator of future results.

Nothing on this website should be construed as investment advice or a recommendation. If you are in any doubt about the suitability of any investment or course of action, you should consult a suitably qualified and regulated financial adviser.

This website is not intended for distribution in any jurisdiction where such distribution would be contrary to local law or regulation.

Site design by

EverQuest Capital Partners Logo

Transforming

industry.

Creating

legacy.

Subscribe to Newsletter

By subscribing you agree that the email provided is subject to our Privacy Policy.

Copyright ©2026. EverQuest Capital Partners

EverQuest Capital Partners LLP ("we", "us", "our") is an appointed representative of Enterprise Investment Partners LLP which is authorised and regulated by the Financial Conduct Authority ("FCA") under firm reference number FRN:604439 Our firm reference number is FRN: 1018153.

This website contains financial promotions that have been approved by Enterprise Investment Partners LLP for the purposes of section 21 of the Financial Services and Markets Act 2000. The information on this website is directed only at persons in the United Kingdom who are:

- Professional clients or eligible counterparties as defined by the FCA; or

- Certified high net worth individuals, self-certified sophisticated investors, or other persons to whom financial promotions may lawfully be made under the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005.


This website and any materials or information contained herein do not constitute an offer to the public or a financial promotion to retail clients unless they meet the criteria above, nor does it constitute a Direct Offer Financial Promotion. Applications for investment may only be made on the basis of the relevant documentation, copies of which are available on request. No reliance is to be placed on the information contained in this website in making such an application.

Investments of the kind referred to in this website are high-risk and are not suitable for all investors. Such investments may be illiquid, volatile, and carry a risk of total loss of capital. Past performance is not a reliable indicator of future results.

Nothing on this website should be construed as investment advice or a recommendation. If you are in any doubt about the suitability of any investment or course of action, you should consult a suitably qualified and regulated financial adviser.

This website is not intended for distribution in any jurisdiction where such distribution would be contrary to local law or regulation.

Site design by

EverQuest Capital Partners Logo

Transforming

industry.

Creating

legacy.

Subscribe to Newsletter

By subscribing you agree that the email provided is subject to our Privacy Policy.

Copyright ©2026. EverQuest Capital Partners

EverQuest Capital Partners LLP ("we", "us", "our") is an appointed representative of Enterprise Investment Partners LLP which is authorised and regulated by the Financial Conduct Authority ("FCA") under firm reference number FRN:604439 Our firm reference number is FRN: 1018153.

This website contains financial promotions that have been approved by Enterprise Investment Partners LLP for the purposes of section 21 of the Financial Services and Markets Act 2000. The information on this website is directed only at persons in the United Kingdom who are:

- Professional clients or eligible counterparties as defined by the FCA; or

- Certified high net worth individuals, self-certified sophisticated investors, or other persons to whom financial promotions may lawfully be made under the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005.


This website and any materials or information contained herein do not constitute an offer to the public or a financial promotion to retail clients unless they meet the criteria above, nor does it constitute a Direct Offer Financial Promotion. Applications for investment may only be made on the basis of the relevant documentation, copies of which are available on request. No reliance is to be placed on the information contained in this website in making such an application.

Investments of the kind referred to in this website are high-risk and are not suitable for all investors. Such investments may be illiquid, volatile, and carry a risk of total loss of capital. Past performance is not a reliable indicator of future results.

Nothing on this website should be construed as investment advice or a recommendation. If you are in any doubt about the suitability of any investment or course of action, you should consult a suitably qualified and regulated financial adviser.

This website is not intended for distribution in any jurisdiction where such distribution would be contrary to local law or regulation.

Site design by